Claim OwnershipBiotechTV - News
Subscribed: 3Played: 35
Subscribe
© BiotechTV
Description
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
387 Episodes
Reverse
He describes learnings from Afrezza's commercialization, why the company acquired scPharmaceuticals, an update on their partnership with United Therapeutics in PAH, and a key IPF asset that is in the pipeline.
He comments on Abivax, Corvus, Iovance, Legend, Terns, and more.
He argues that investors are too focused on each percentage of weight loss and not focused enough on the tolerability of new options. He discusses the timeline for the phase 3 that will likely start later this year, and how it might look different than the phase 2 study that just read out.
Maneet Singh says that pharma companies need to keep buying, and have the financial wherewithal to do it. He also gives thoughts on which areas within biotech could attract the most interest.
CEO Greg Mayes describes the science behind luvesilocin, which is a prodrug of 4-OH-DiPT, a psilocybin-like compound, and discusses the company's plans for a phase 3 study. Plus, comments on two other indications the company is pursuing.
He gives his take on two questions being discussed the most: 1) is AXPAXLI approvable on one study and 2) how might physicians think about using it in practice.
He highlights pipeline programs targeting ENPP3, CLDN6, CLDN18.2, TL1A (including TL1A x IL23p19), CD20 x CD3, and CD19xCD3.
President & CEO Nancy Whiting discusses the historical difficulties in drugging SH2, and describes the company's discovery platform that enables it today. A STAT6 program is already dosing in the clinic, and Sanofi has a partnership on it. Plus, a BTK, and a recent financing that Lilly participated in.
She discusses uniQure, Moderna, BridgeBio, Gossamer Bio and more.
He shares highlights from data announced at the end of the year, and what Janux has learned about the program's dosing and safety mitigation profile. Also, why he has his sights set on the FcRn market when he thinks about the company's CD19.
He discusses the company's third year in a row of revenue growth, and the new products that have helped Teva get there. Plus, a potential near-term approval for a monthly dosed schizophrenia product, and the lates on IL-15 and TL1A.
CEO Nima Farzan explains the science behind Nav1.8, why he believes Latigo's asset could be best in class, and the status of the company's development program.
Randy Teel updates us on effectors to find a commercialization partner for the ER degrading PROTAC that is in front of FDA right now with a June 5 decision date scheduled. Plus, discussing programs targeting KRAS, BCL6, polyQ-AR and more.
President and CEO Kathy Dong describes the function of SIRPs and how Electra is targeting them with antibodies. Plus, an overview of the company's privotal program against secondary Hemophagocytic Lymphohistiocytosis (sHLH).
CEO Ron Cooper describes why you need an alternative to virally delivered products for indications like bladder cancer. Plus, previewing a data update in the spring and 12 month data by the end of the year.
He believes that the sector's fundamentals are strong and that M&A, which played a central role in boosting biotech last year, can keep up in 2026. Plus, he believes there is a good supply of quality IPOs in the queue that can meet demand that has been there for a while.
CEO Iain McGill describes the "Chill, not Kill" approach that Quell is taking with its Treg platform, which integrates a FOXP3 phenotype lock in addition to the CAR. Plus, an update on the company's liver transplant study, a program that he says will need a partner to move forward.
CEO Dinesh Patel and Chief Discovery Officer Ashok Bhandari walk us through the company's R&D expertise, and we discuss programs covering IL-23, IL-17, a hepcidin mimetic, and obesity medicines.
CEO Sarah Howell discusses three key aspects of the business: helping with reformulation, its own proprietary insulin products, and developing oral peptides like GLPs.
Co-Founder & President Jacob Kimmel describes the science behind how this works, and the enormous amount of work that goes into choosing which transcription factors to target. The company is currently in IND enabling studies.
Comments
Download from Google Play
Download from App Store
United States